| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 80.7 | 71.9 |
| Gross profit | 46.2 | 41.3 |
| Profit before tax | 6.8 | 5.1 |
| Net income | 4.6 | 3.5 |
| EPS (diluted, $ a share) | $0.11 | $0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +32.0% |
|---|---|
| Revenue, year on year | +12.2% |
| Gross margin | 57.3% |
| Operating margin | 8.6% |
10-Q filed with the SEC, NASDAQ: VMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Viemed Healthcare, Inc.: key numbers
- Share price
- $9.15Close, Nov 16
- Market cap
- $347M
- Shares outstanding
- 37.89MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Misc Health & Allied Services, NECSIC 8090
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Viemed Healthcare, Inc.
All →Viemed Healthcare Earnings Call: Key Takeaways
Viemed delivered record revenue of $80.7 million and 32% net income growth, driven by strong sleep therapy performance and maternal health expansion despite audit-related cash flow delays.
- Call
- Nov 5, 2026, 11:00 AM ET
Viemed Healthcare Financial Results
Viemed Healthcare reported record third-quarter 2026 net revenue of $80.7 million, a 12.2% year-over-year increase driven by growth in ventilator and PAP therapy patient volumes. The company raised the low end of its full-year 2026 revenue guidance to a range of $316 million to $320 million and improved its net capital expenditure outlook.
- Term
- Q3 2026
“Viemed delivered another record quarter, with revenue reaching $80.7 million and continued growth across our respiratory, sleep, and women's health businesses.”
Casey Hoyt, Viemed’s CEO